Literature DB >> 1712268

Effects of ACE inhibition on renal haemodynamics in essential hypertension and hypertension associated with chronic renal failure.

R A Sánchez1, C A Traballi, E J Marcó, B H Gilbert, A J Ramírez, G Long.   

Abstract

Angiotensin II has many actions in the kidney, including regulation and distribution of renal circulation and glomerular filtration, as well as effects on mesangial contraction and on the filtration coefficient. The reduction in circulating and intrarenal angiotensin II by angiotensin converting enzyme (ACE) inhibitors in essential hypertension is associated with a significant increase in renal blood flow and a decrease in filtration fraction, without changes in glomerular filtration rate. In addition, administration of ACE inhibitors can reduce proximal sodium reabsorption via changes in peritubular hydrostatic and oncotic forces resulting from the fall in postglomerular capillary resistance. In severe hypertension the state of the renal vasculature does not allow ACE inhibition to induce similar haemodynamic changes and, therefore, it cannot contribute to renal sodium handling that requires the recruitment of alternate mechanisms. In spite of this, ACE inhibitors may exert a protective effect on the renal function of patients with severe hypertension as well as in those with renal impairment, by lowering systemic and, probably, intraglomerular pressure, reducing proteinuria and slowing the progression of renal failure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712268     DOI: 10.2165/00003495-199100411-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  8 in total

1.  Enalapril and the kidney: renal vasodilation and natriuresis due to the inhibition of angiotensin II formation.

Authors:  G J Navis; D de Zeeuw; P E de Jong
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

2.  The renal vasculature in early essential hypertension: evidence for a pathogenetic role.

Authors:  N K Hollenberg; L J Borucki; D F Adams
Journal:  Medicine (Baltimore)       Date:  1978-03       Impact factor: 1.889

3.  Measurement of renal clearance of inulin and PAH in the steady state without urine collection.

Authors:  E Schnurr; W Lahme; H Küppers
Journal:  Clin Nephrol       Date:  1980-01       Impact factor: 0.975

4.  Simplified hippuran clearance. Measurement of renal function in man with simplified hippuran clearances.

Authors:  M D Blaufox; J P Merrill
Journal:  Nephron       Date:  1966       Impact factor: 2.847

5.  Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.

Authors:  S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

6.  Renal hemodynamics in patients with sustained essential hypertension and in patients with unilateral stenosis of the renal artery.

Authors:  G M London; M E Safar
Journal:  Am J Hypertens       Date:  1989-04       Impact factor: 2.689

Review 7.  Angiotensin converting enzyme inhibitors and renal function.

Authors:  A Mimran; J Ribstein
Journal:  J Hypertens Suppl       Date:  1989-09

8.  Physiological effects of short-term treatment with enalapril in hypertensive patients.

Authors:  P W de Leeuw; R P Hoogma; G A van Soest; P N van Es; W H Birkenhäger
Journal:  J Hypertens Suppl       Date:  1983-10
  8 in total
  2 in total

Review 1.  Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.

Authors:  Lin-Lin Liu; Yi Jiang; Li-Ning Wang; Li Yao; Zi-Long Li
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

Review 2.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.